Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carboplatin + paclitaxel with or without sorafenib in previously untreated advanced non-small cell lung cancer
2005-005245-19Phase 3Terminated
- Sponsor
- Bayer
- Start
- Feb 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Sorafenib + paclitaxel + carboplatin with Placebo + paclitaxel + carboplatin (2 arms). Primary endpoint: Overall survival. Started Feb 2006; status: terminated.
02
Drugs
sorafenib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2005-005245-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005245-19.